Scarica l'app Stockscreener
40.94
2.08%
-0.87
Dopo l'orario di chiusura:
40.72
-0.22
-0.54%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook - TradingView
Did Phase 2 Trial Win Just Shift Roivant Sciences (ROIV) Investment Narrative? - simplywall.st
ROIV: Robust pipeline advances and strong financials set the stage for multiple upcoming launches - TradingView
Why Did Roivant (NASDAQ:ROIV) Shares Surge on Study Results? - Kalkine Media
A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $46 to $55 - Moomoo
ROIV Maintains Buy Rating -- Price Target Raised to $55 - GuruFocus
Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial - Pulse 2.0
H.C. Wainwright raises Roivant Sciences price target on trial data - Investing.com
Guggenheim raises Roivant Sciences stock price target on trial data - Investing.com
Roivant Sciences Stock Rallies 20% On Positive Phase 2 Trial Results For Pulmovant Drug - TIKR.com
Roivant Sciences stock surges on positive PH-ILD trial data By Investing.com - Investing.com Australia
TD Cowen raises Roivant Sciences stock price target on trial data - Investing.com India
Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41% - Yahoo Finance
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $55 - Moomoo
Why is Roivant Sciences stock surging today? By Investing.com - Investing.com Australia
Biotech Trial Wins Sent Roivant And Pharvaris Higher - Finimize
ROIV Looks 472.1% Overvalued on GF Value™ Amid Clinical Trial Su - GuruFocus
Roivant Sciences soars 19% on positive mosliciguat trial results (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences (NASDAQ: ROIV) director moves to sell shares after option exercise - Stock Titan
Roivant Sciences Surges 17.7% Amid Sector-Wide Rally - AlphaStreet
ROIV Maintained by HC Wainwright & Co. -- Price Target Raised to $47 - GuruFocus
These 2 Biotech Stocks Hit Record Highs Today – What’s Driving The Rallies? - Yahoo Finance
Roivant shares jump 17% as lung disease drug meets trial goals - Investing.com Canada
Jefferies raises Roivant Sciences stock price target on trial data By Investing.com - Investing.com South Africa
Roivant Sciences price target jumps 24.7% after strong Phase 2 trial for lung disease drug - Pluang
Roivant Sciences Stock Soars as Experimental Inhaled Drug Hits Mid-Stage Trial Goals - barrons.com
ROIV Stock Jumps As FDA Clears LISRAYA And Analysts Hike Targets - StocksToTrade
ROIV Stock Jumps As LISRAYA FDA Approval Ignites Momentum - timothysykes.com
Roivant at Wells Fargo conference: pipeline momentum lifts outlook By Investing.com - Investing.com Canada
Transcript : Roivant Sciences Ltd. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 10:15 AM - marketscreener.com
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings - Benzinga
Jefferies Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $52 - Moomoo
Roivant Shares Surge as Mosliciguat Hits Primary Endpoint in Phase 2 PH-ILD Study - Minichart
Roivant's experimental lung disease drug meets goals in mid-stage study - reuters.com
Roivant Sciences Rallies as Mosliciguat Phase 2 Data Beat Key Endpoints - quiverquant.com
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy - Yahoo Finance
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data - BioSpace
Roivant Sciences stock hits all-time high at 39.99 USD By Investing.com - Investing.com Nigeria
Roivant Sciences stock surges on positive PH-ILD trial data - Investing.com
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Roivant Sciences stock hits all-time high at 39.99 USD - Investing.com
ROIV: Mosliciguat delivered unprecedented PVR reduction and functional gains in PH-ILD, with strong safety - TradingView
Up to 200,000 PH-ILD patients lack options as Roivant (NASDAQ: ROIV) moves mosliciguat into a Phase 3 trial - Stock Titan
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate - Yahoo Finance
ROIV Looks 381.9% Overvalued on GF Value™ - GuruFocus
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director - GlobeNewswire Inc.
Roivant reports mosliciguat Phase 2 PH-ILD results - grafa.com
Roivant’s Experimental Lung Disease Drug Hits Key Phase 2 Goal – ROIV Stock Tracks All-Time High - Yahoo Finance
Why Is ROIV Stock Tracking Record Highs In Pre-Market Today? - Stocktwits
S&P 500 Futures Decline in Premarket Trading; Roivant Sciences, Bloom Energy Lead - Barron's
Roivant stock climbs on mid-stage trial win (ROIV:NASDAQ) - Seeking Alpha
Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results - Yahoo Finance
Roivant reports positive phase 2 trial results for mosliciguat By Investing.com - Investing.com Nigeria
Why is Roivant Sciences stock surging today? - Investing.com
Roivant’s Mosliciguat Heads To Phase III After 56% PVR Reduction In PH-ILD - insights.citeline.com
Up to 200,000 people live with this lung disease. Roivant starts a new trial. - Stock Titan
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):